• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Broadening of COVIDITY Phase 1 clinical trial in South Africa

by admin | Mar 29, 2022 | Covid-19, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab™

by admin | Mar 17, 2022 | GlyMab, Latest News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

PAD-2- mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy

by admin | Feb 14, 2022 | Moditope, Vaccines

Ruhul H Choudhury, Peter Symonds, Samantha J Paston, Ian Daniels, Katherine W Cook, Mohamed Gijon, Rachael L Metheringham, Victoria A Brentville, Lindy G Durrant ABSTRACT:Background The enzymatic conversion of arginine to citrulline is involved in gene and protein...

An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma

by admin | Feb 14, 2022 | Antibodies, Glymab

Ruben D. Houvast, Kira Thijse, Jesse V. Groen, JiaXin Chua, Mireille Vankemmelbeke, Lindy G. Durrant, J. Sven D. Mieog, Bert A. Bonsing, Alexander L. Vahrmeijer, Peter J.K. Kuppen, A. Stijn L.P. Crobach and Cornelis F. M. Sier SIMPLE SUMMARY: Distinguishing pancreatic...

Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging

by admin | Feb 14, 2022 | Antibodies, Glymab

Ruben D. Houvast, Mireille Vankemmelbeke, Lindy G. Durrant, Manfred Wuhrer, Victor M. Baart, Peter J.K. Kuppen, Lioe-Fee de Geus-Oei, Alexander L. Vahrmeijer and Cornelis F.M. Sier SIMPLE SUMMARY:  Distinguishing malignancy from healthy tissue is essential for...
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy